MDS Current Trials UK
- SUB-TYPE OF MDS: All subtypes of MDS.
- SEVERITY OF MDS: High Risk MDS and Acute myeloid leukaemia.
- NAME OF DRUG: CCS-1477
- SUB-TYPE OF MDS: All subtypes of MDS.
- SEVERITY OF MDS: Intermediate or High Risk MDS and Acute myeloid leukaemia.
- NAME OF DRUG: PDR001, MBG453
- SUB-TYPE OF MDS: All Subtypes
- SEVERITY OF MDS: Intermediate, High or Very High Risk
- NAME OF DRUG: Venetoclax
- SUB-TYPE OF MDS: Patients with relapsed/refractory AML or AML secondary to myeloproliferative neoplasm.
- SEVERITY OF MDS: Intermediate, High or Very High Risk
- NAME OF DRUG: KRT-232
- SUB-TYPE OF MDS: Patients with MDS or CMML who have relapsed from or are refractory to previous therapy
- SEVERITY OF MDS: Intermediate, High or Very High Risk
- NAME OF DRUG: EP0042
- SUB-TYPE OF MDS: MDS patients and Chronic Myelomonocytic leukaemia -2 patients who require first-line treatment
- SEVERITY OF MDS: Intermediate, High or Very High Risk
- NAME OF DRUG: Sabatolimab (MBG453)
- SUB-TYPE OF MDS: Low risk MDS patients
- SEVERITY OF MDS: IPSS Low or Intermediate-1 risk MDS
- NAME OF DRUG: Imetelstat
- SUB-TYPE OF MDS:Low risk MDS patients who have participated in other Luspatercept clinical trials
- SEVERITY OF MDS: IPSS-R Very Low, Low or Intermediate Risk MDS
- NAME OF DRUG: Luspatercept
- SUB-TYPE OF MDS:Patients newly diagnosed with CD123 positive adverse genetic risk acute myeloid leukaemia (AML), including patients with CD123 positive AML secondary to MDS
- SEVERITY OF MDS: AML
- NAME OF DRUG: UCART targeting CD123 positive leukaemia cells
- SUB-TYPE OF MDS:Patients AML (acute myeloid leukaemia) who fail to enter morphological remission or have persistence of cytogenetic abnormality following intensive combination chemotherapy at day+100 post-transplant
- SEVERITY OF MDS: AML
- NAME OF DRUG: Lentivirus Transduced Acute Myeloid Leukaemic Cells (AML) that express
B7.1 (CD80) and IL-2 (AML cell vaccine)
